Media stories about Assembly Biosciences (NASDAQ:ASMB) have been trending positive on Thursday, Accern reports. The research firm ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Assembly Biosciences earned a media sentiment score of 0.26 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 45.6360895779166 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Assembly Biosciences (NASDAQ ASMB) traded down 0.61% during trading on Thursday, reaching $34.38. The company had a trading volume of 35,382 shares. The company’s market capitalization is $596.97 million. Assembly Biosciences has a one year low of $10.75 and a one year high of $36.31. The firm’s 50 day moving average is $30.72 and its 200 day moving average is $25.14.

Several equities analysts recently issued reports on ASMB shares. BidaskClub upgraded Assembly Biosciences from a “strong sell” rating to a “sell” rating in a research report on Thursday, August 3rd. Zacks Investment Research lowered Assembly Biosciences from a “hold” rating to a “sell” rating in a research report on Monday, August 14th. Finally, Chardan Capital restated a “buy” rating on shares of Assembly Biosciences in a research report on Sunday, September 17th.

TRADEMARK VIOLATION NOTICE: “Positive Media Coverage Somewhat Unlikely to Impact Assembly Biosciences (ASMB) Stock Price” was originally reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at

About Assembly Biosciences

Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.

Insider Buying and Selling by Quarter for Assembly Biosciences (NASDAQ:ASMB)

Receive News & Ratings for Assembly Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.